Our top pick for
Galera Therapeutics, Inc is a biotechnology business based in the US. Galera Therapeutics shares (GRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Galera Therapeutics employs 38 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$6.15 - $15.00|
|50-day moving average||$8.95|
|200-day moving average||$10.48|
|Wall St. target price||$19.60|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.40|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$0|
|Return on assets TTM||-42.51%|
|Return on equity TTM||-196.02%|
|Market capitalisation||$165.1 million|
TTM: trailing 12 months
There are currently 160,601 Galera Therapeutics shares held short by investors – that's known as Galera Therapeutics's "short interest". This figure is 4.8% up from 153,228 last month.
There are a few different ways that this level of interest in shorting Galera Therapeutics shares can be evaluated.
Galera Therapeutics's "short interest ratio" (SIR) is the quantity of Galera Therapeutics shares currently shorted divided by the average quantity of Galera Therapeutics shares traded daily (recently around 70439.035087719). Galera Therapeutics's SIR currently stands at 2.28. In other words for every 100,000 Galera Therapeutics shares traded daily on the market, roughly 2280 shares are currently held short.
However Galera Therapeutics's short interest can also be evaluated against the total number of Galera Therapeutics shares, or, against the total number of tradable Galera Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Galera Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Galera Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0217% of the tradable shares (for every 100,000 tradable Galera Therapeutics shares, roughly 22 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Galera Therapeutics.
Find out more about how you can short Galera Therapeutics stock.
We're not expecting Galera Therapeutics to pay a dividend over the next 12 months.
Galera Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. .
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.